Awake prone positioning does not reduce the risk of intubation in COVID-19 treated with high-flow nasal oxygen therapy: a multicenter, adjusted cohort study

Table 3 Associations between HFNO plus awake prone positioning and the endpoint of intubation and 28-day mortality in the original population and weighted population

Analysis	Hazard ratio (95% CI); p value
Intubation
Crude analysis	0.879 (0.538, 1.435); p = 0.60
Inverse probability weighting analysis	1.002 (0.531, 1.890); p = 0.99
28-day mortality
Crude analysis	1.046 (0.402, 2.722); p = 0.92
Inverse probability weighting analysis	2.411 (0.556, 10.442); p = 0.23

Logistic models were fitted to predict treatment at baseline using the following variables as predictors of treatment: age, sex, obesity, non-respiratory sequential organ failure assessment severity score, APACHE II, C-reactive protein, days from symptoms onset to high-flow nasal therapy start, respiratory rate, and peripheral oxyhemoglobin saturation
CI confidence interval

ISSN: 1364-8535